Lupin, Mylan partner on global Enbrel biosimilar
Mylan, fresh off the recent U.S. approval of its Neulasta biosimilar Fulphila, created through a partnership with Biocon, is striking a similar partnership with Lupin. The two companies will work together to commercialize Lupin’s biosimilar of Enbrel (etanercept), which it has already submitted for European Medicines Agency for approval.
Under the agreement, Mylan will commercialize the product in Europe, Australia, New Zealand, Latin America, Africa and most Asian markets. Enbrel’s global brand sales in 2017 were $11.6 billion, according to IQVIA data for the 12 months ended Dec. 31, 2017.
“The collaboration with Lupin is yet another positive step in our ongoing efforts to bring key biosimilars, like etanercept, to patients around the world as quickly as possible,” said Mylan CEO Heather Bresch. “The introduction of biosimilars is an important mechanism to help increase access to more affordable biologics treatments, and our industry-leading portfolio of 20 biosimilar products positions Mylan to be at the forefront of delivering those savings.”
The agreement will see Mylan paying Lupin $15 million upfront, with the potential for commercial milestones alongside an equal share in net profits of the product.
“We are extremely pleased to announce this partnership as both Lupin and Mylan share a commitment to bring affordable and high-quality medicines to market, especially in areas of unmet need,” Lupin said. “Mylan is well-positioned to commercialize our Etanercept biosimilar given their significant expertise and global infrastructure. This partnership enables us to accelerate our Etanercept market plans across multiple regions globally, as we continue to advance our pipeline of biosimilar candidates.”
Under the agreement, Mylan will commercialize the product in Europe, Australia, New Zealand, Latin America, Africa and most Asian markets. Enbrel’s global brand sales in 2017 were $11.6 billion, according to IQVIA data for the 12 months ended Dec. 31, 2017.
“The collaboration with Lupin is yet another positive step in our ongoing efforts to bring key biosimilars, like etanercept, to patients around the world as quickly as possible,” said Mylan CEO Heather Bresch. “The introduction of biosimilars is an important mechanism to help increase access to more affordable biologics treatments, and our industry-leading portfolio of 20 biosimilar products positions Mylan to be at the forefront of delivering those savings.”
The agreement will see Mylan paying Lupin $15 million upfront, with the potential for commercial milestones alongside an equal share in net profits of the product.
“We are extremely pleased to announce this partnership as both Lupin and Mylan share a commitment to bring affordable and high-quality medicines to market, especially in areas of unmet need,” Lupin said. “Mylan is well-positioned to commercialize our Etanercept biosimilar given their significant expertise and global infrastructure. This partnership enables us to accelerate our Etanercept market plans across multiple regions globally, as we continue to advance our pipeline of biosimilar candidates.”